Mirum Pharmaceuticals (MIRM) Equity Ratio (2018 - 2026)

Mirum Pharmaceuticals' Equity Ratio history runs 9 years deep, the most recent figure standing at 0.27 for Q1 2026.

• In Q1 2026, Equity Ratio fell 19.46% year-over-year to 0.27; the TTM figure through Mar 2026 stood at 0.27 (down 19.46% YoY), while the FY2025 annual figure was 0.37, up 10.99% from the prior year.
• Equity Ratio was 0.27 for Q1 2026 at Mirum Pharmaceuticals, down from 0.37 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.46 in Q3 2022 to a low of 0.18 in Q2 2023.
• Historically, Equity Ratio has averaged 0.36 across 5 years, with a median of 0.37 in 2025.
• The sharpest annual moves came in 2023 and 2024: Equity Ratio sank 52.41% in 2023, then surged 95.56% in 2024.
• A 5-year view of Equity Ratio shows it stood at 0.4 in 2022, then slipped by 4.45% to 0.38 in 2023, then dropped by 12.53% to 0.34 in 2024, then advanced by 10.99% to 0.37 in 2025, then dropped by 27.1% to 0.27 in 2026.
• The last three Equity Ratio figures came in at 0.27 (Q1 2026), 0.37 (Q4 2025), and 0.37 (Q3 2025), per Business Quant data.